Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Myriad Genetics
ISIN US62855J1043
|WKN 897518
Market cap (in EUR)
385 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Healthcare Healthcare Equipment Diagnostics and Drug Delivery Devices United States
Financials
Key metrics
| Market capitalisation, EUR | 385 m |
| EPS, EUR | -3.50 |
| P/B ratio | 1.2 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 731 m |
| Net income, EUR | -324 m |
| Profit margin | -44.38% |
What ETF is Myriad Genetics in?
There is 1 ETF which contains Myriad Genetics.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETF | 0.03% | Equity United States Small Cap | 2,284 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.